Clinical trial
A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis
NCT06135415 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis
- Lead sponsor
- Almirall, S.A.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 21, 2023
- Completion date
- November 25, 2025
- Enrollment
- 280 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.